140 related articles for article (PubMed ID: 10233456)
1. Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand.
Colls BM; Harvey VJ; Skelton L; Frampton CM; Thompson PI; Bennett M; Perez DJ; Dady PJ; Forgeson GV; Kennedy IC
BJU Int; 1999 Jan; 83(1):76-82. PubMed ID: 10233456
[TBL] [Abstract][Full Text] [Related]
2. Primary chemotherapy after orchidectomy for stage I and II nonseminoma.
Horwich A; Cullen MH; Stenning SP
Semin Oncol; 1998 Apr; 25(2):154-9. PubMed ID: 9562448
[TBL] [Abstract][Full Text] [Related]
3. The value of prognostic factors in the management of stage I nonseminomatous germ cell testicular tumors (NSGCTT).
Ondrus D; Goncalves F; Kausitz J; Mat'oska J; Belan V
Neoplasma; 1996; 43(3):195-7. PubMed ID: 8841507
[TBL] [Abstract][Full Text] [Related]
4. [Results of 15 years of treatment of nonseminoma testicular cancer: 84% 5-year survival rate].
van Veelen LR; Steyerberg EW; Cleton FJ; Keizer HJ
Ned Tijdschr Geneeskd; 1999 Mar; 143(11):564-8. PubMed ID: 10321275
[TBL] [Abstract][Full Text] [Related]
5. Laparoscopic retroperitoneal lymph node dissection combined with adjuvant chemotherapy for pathological stage II disease in nonseminomatous germ cell tumours: a 15-year experience.
Cresswell J; Scheitlin W; Gozen A; Lenz E; Teber D; Rassweiler J
BJU Int; 2008 Sep; 102(7):844-8. PubMed ID: 18537954
[TBL] [Abstract][Full Text] [Related]
6. Results of the surveillance policy of stage I non-seminomatous germ cell testicular tumours.
Colls BM; Harvey VJ; Skelton L; Thompson PI; Dady PJ; Forgeson GV; Perez DJ
Br J Urol; 1992 Oct; 70(4):423-8. PubMed ID: 1333336
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment.
Ondrus D; Matoska J; Belan V; Kausitz J; Goncalves F; Hornák M
Eur Urol; 1998; 33(6):562-6. PubMed ID: 9743698
[TBL] [Abstract][Full Text] [Related]
8. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
[TBL] [Abstract][Full Text] [Related]
9. [Management of stage I testicular nonseminomatous germ cell tumors with an embryonic carcinomatous component. 18 cases].
Drianno N; Robert M; Legouffe E; Guiter J; Navratil H
Prog Urol; 1997 Sep; 7(4):622-7. PubMed ID: 9410322
[TBL] [Abstract][Full Text] [Related]
10. [Use of prognostic factors of disease progression in the treatment of patients with stage I nonseminomatous testicular tumors].
Ondrus D
Bratisl Lek Listy; 1999 Jan; 100(1):61-5. PubMed ID: 10493000
[TBL] [Abstract][Full Text] [Related]
11. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience.
Gels ME; Hoekstra HJ; Sleijfer DT; Marrink J; de Bruijn HW; Molenaar WM; Freling NJ; Droste JH; Schraffordt Koops H
J Clin Oncol; 1995 May; 13(5):1188-94. PubMed ID: 7537802
[TBL] [Abstract][Full Text] [Related]
12. Late relapse in stage I of nonseminomatous germ cell testicular cancer on surveillance.
Ondrusova M; Suchansky M; Psota M; Zeleny T; Ondrus D
Bratisl Lek Listy; 2018; 119(1):3-5. PubMed ID: 29405722
[TBL] [Abstract][Full Text] [Related]
13. Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations.
Conduit C; Lewin J; Weickhardt A; Lynam J; Wong S; Grimison P; Sengupta S; Pranavan G; Parnis F; Bastick P; Campbell D; Hansen AR; Leonard M; McJannett M; Stockler MR; Gibbs P; Toner G; Davis ID; Tran B; Kuchel A
JCO Oncol Pract; 2023 Nov; 19(11):973-980. PubMed ID: 37327464
[TBL] [Abstract][Full Text] [Related]
14. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only.
Ondrus D; Ondrusova M; Hornak M; Matoska J
Neoplasma; 2007; 54(5):437-42. PubMed ID: 17688374
[TBL] [Abstract][Full Text] [Related]
15. Risk-adapted management for patients with clinical stage I non-seminomatous germ cell tumour of the testis.
Guney S; Guney N; Sonmez NC; Ergenekon E
Med Oncol; 2009; 26(2):136-42. PubMed ID: 18821067
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy.
Oliver RT; Ong J; Shamash J; Ravi R; Nagund V; Harper P; Ostrowski MJ; Sizer B; Levay J; Robinson A; Neal DE; Williams M;
Urology; 2004 Mar; 63(3):556-61. PubMed ID: 15028457
[TBL] [Abstract][Full Text] [Related]
17. Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options.
Francis R; Bower M; Brunström G; Holden L; Newlands ES; Rustin GJ; Seckl MJ
Eur J Cancer; 2000 Oct; 36(15):1925-32. PubMed ID: 11000572
[TBL] [Abstract][Full Text] [Related]
18. Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors.
Spermon JR; Roeleveld TA; van der Poel HG; Hulsbergen-van de Kaa CA; Ten Bokkel Huinink WW; van de Vijver M; Witjes JA; Horenblas S
Urology; 2002 Jun; 59(6):923-9. PubMed ID: 12031382
[TBL] [Abstract][Full Text] [Related]
19. Surveillance in stage I testicular seminoma - risk of late relapse.
Chung P; Parker C; Panzarella T; Gospodarowicz MK; Jewett S; Milosevic MF; Catton CN; Bayley AJ; Tew-George B; Moore M; Sturgeon JF; Warde P
Can J Urol; 2002 Oct; 9(5):1637-40. PubMed ID: 12431325
[TBL] [Abstract][Full Text] [Related]
20. Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
Heidenreich A; Paffenholz P; Nestler T; Pfister D
Oncol Res Treat; 2018; 41(6):370-378. PubMed ID: 29772568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
